Safety of Adrenaline Use in Anaphylaxis: A Multicentre Register

Clinical guidelines prioritize intramuscular adrenaline for managing anaphylaxis, yet real-world application remains inconsistent. Practitioners often hesitate to administer this life-saving medication due to concerns regarding potential safety profiles. No prior work had resolved the exact frequency of adverse events in diverse patient populations. That uncertainty drove the need for a comprehensive assessment of registry data. Prior research has shown that perceived risks often outweigh documented clinical evidence in emergency settings. This gap motivated a systematic evaluation of patient outcomes following standard treatment protocols. Understanding the true incidence of complications is necessary for improving adherence to established medical directives. Such clarity helps clinicians balance immediate therapeutic benefits against the possibility of transient physiological responses.

The aim of this study was to assess the incidence and severity of adverse side effects after the use of adrenaline in anaphylaxis. Researchers also sought to identify potential risk factors contributing to these physiological responses. This work addresses the persistent issue of suboptimal treatment application in emergency settings. Many practitioners avoid the recommended first-line therapy due to fears regarding patient safety. That uncertainty drove the need for a rigorous examination of real-world registry data. No prior work had resolved the true prevalence of complications in this specific patient population. This study provides evidence to support informed decision-making during acute allergic crises. The motivation was to clarify whether safety concerns warrant the current hesitation observed in clinical practice.

The investigation employed an observational design utilizing a multicenter online registry. Review approach involved the systematic collection of 277 valid clinical cases. Researchers documented patient demographics, including age and sex, for all included participants. The team categorized administration routes to compare intramuscular delivery against other methods. Data analysis focused on identifying statistical associations between treatment variables and adverse outcomes. Investigators defined specific criteria for mild versus potentially severe physiological responses. This methodology ensured a standardized evaluation of reported side effects across different medical centers. The approach prioritized transparency in recording both common symptoms and rare cardiovascular events.

Key findings from the literature indicate that side effects occurred in 58 cases, representing 21.64% of the total cohort. Tremors, palpitations, and anxiety emerged as the most frequently reported symptoms among patients. Potentially severe adverse events, such as high blood pressure or electrocardiogram alterations, affected only 8 individuals, or 2.99%. Statistical analysis revealed that older age, higher medication doses, and intravenous administration were associated with increased side effects. In cases of severe events, no significant differences appeared regarding age or dosage. However, intravenous delivery remained consistently linked to more serious complications throughout the analysis. The data demonstrate that fewer than one in five patients experience any adverse reaction. These reactions are typically characterized as mild and transient in nature.

The authors conclude that adverse reactions occur in a minority of patients receiving adrenaline for anaphylaxis. Most observed symptoms remain mild and resolve quickly without long-term complications. Intravenous administration appears to correlate with a higher likelihood of both common and severe events. The researchers propose that withholding treatment based on safety fears lacks clinical justification in most scenarios. These findings emphasize the importance of prioritizing rapid intervention during acute allergic crises. Clinicians should recognize that serious cardiovascular or electrocardiographic changes are exceptionally rare occurrences. The evidence supports maintaining current guidelines that advocate for timely intramuscular delivery. Future practice should focus on overcoming barriers to effective emergency care delivery.